Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis is a lung disease with limited therapeutic options that is characterized by pathological fibroblast activation and aberrant lung remodeling with scar formation. YAP (Yes-associated protein) is a transcriptional coactivator that mediates mechanical and biochemical signals controlling fibroblast activation. In this study, we developed a high-throughput small-molecule screen for YAP inhibitors in primary human lung fibroblasts. Multiple HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase inhibitors (statins) were found to inhibit YAP nuclear localization via induction of YAP phosphorylation, cytoplasmic retention, and degradation. We further show that the mevalonate pathway regulates YAP activation, and that simvastatin treatment reduces fibrosis markers in activated human lung fibroblasts and in the bleomycin mouse model of pulmonary fibrosis. Finally, we show that simvastatin modulates YAP in vivo in mouse lung fibroblasts. Our results highlight the potential of small-molecule screens for YAP inhibitors and provide a mechanism for the antifibrotic activity of statins in idiopathic pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Statins, including simvastatin, have also shown antifibrotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“Plates were monitored for cell density, percentage of nuclear YAP(1) cells in control wells, and z-scores (26), and rescreened if deemed necessary.”
BackgroundRole of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 6×
“Accordingly, statins induced a marked increase in the phosphorylation of serine 397 (pS397) (Figures 3A and 3B), which marks YAP for proteasomal degradation (28).”
BackgroundInfluentialTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“Statin treatment was associated with decreased cell numbers (Figure E3A), probably due to inhibition of proproliferative YAP/TAZ signaling (27).”
BackgroundMethodSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 2×
“YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are transcriptional coactivators that when active translocate to the nucleus and induce the expression of a wide range of genes, controlling cell proliferation, survival, and migration (10).”
BackgroundAragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651 · cited 8×
“In our investigation of the antifibrotic potential of statins, we also found that statins Santos, Pantano, Pronzati, et al.: IPF Drug Screen: Statins Inhibit YAP in Lung Fibroblasts 489 prevented HLF activation by TGF-b, reducing the expression of profibrotic genes (CTGF, CYR61, ACTA2, and COL1A1) and preventing actin…”
BackgroundInfluential
Research works printed but not linked: 1
- Santos DM, Pantano L, Pronzati G, Grasberger P, Probst CK, Black KE, et al. A high-throughput small molecule screen for YAP inhibitors identifies statins as inhibitors of fibroblast activation and pulmonary fibrosis [abstract] Am J Respir Crit Care Med. 2019;199:A5878. [Google Scholar]
Cited by
The extracellular matrix and mechanotransduction in pulmonary fibrosis
Deng, Z., Fear, M. W., Suk Choi, Y., Wood, F. M., Allahham, A., Mutsaers, S. E., & Prêle, C. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105802 · Cited by 120
New Insights into Hippo/YAP Signaling in Fibrotic Diseases
Mia, M. M., & Singh, M. K. (2022) · Cells · doi:10.3390/cells11132065 · Cited by 116
“This study found that simvastatin modulates YAP localization in mouse lung fibroblasts in vivo and reduces established fibrosis in bleomycin-challenged mouse IPF (Table 1) [67].”
BackgroundInfluentialFibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 154
“Several statins recently emerged from high-throughput screens with small-molecule libraries as possible regulators of YAP signalling and drugs that target the mevalonate pathway in human lung fibroblasts 126 .”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Hippo signaling pathway and respiratory diseases
Tang, W., Li, M., Yangzhong, X., Zhang, X., Zu, A., Hou, Y., Li, L., & Sun, S. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01020-6 · Cited by 90
“Lung fibroblasts are the main effector cells of IPF, and the YAP mediates the proliferation, migration, and collagen deposition of lung fibroblasts induced by mechanical signals [100, 101].”
BackgroundThe Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
Transcription factors in fibroblast plasticity and CAF heterogeneity
Melchionna, R., Trono, P., Carlo, A. D., Modugno, F. D., & Nisticò, P. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02934-4 · Cited by 96
“Statins, via inhibition of HMG-CoA reductase, have been found to impede YAP/TAZ nuclear localization, attenuating established lung fibrosis in a mouse model [141].”
BackgroundEzzo, M., Spindler, K., Wang, J. B., Lee, D., Pecoraro, G., Cowen, J., Pakshir, P., & Hinz, B. (2024) · Science Advances · doi:10.1126/sciadv.adp4726 · Cited by 82
“Such converging signaling effects of YAP in fibrosis, in addition to mechanical stress, have been reported for signaling through statins ( 73 ) and specific G protein–coupled receptors ( 74 ).”
BackgroundOrtega, Á., Vera, I., Díaz, M. I., Navarro, C., Rojas, M., Torres, W., Parra, H., Salazar, J. J., Sanctis, J. B. D., & Bermúdez, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010430 · Cited by 94
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy
Chen, R., & Dai, J. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02336-1 · Cited by 85
“observed that statins were able to inactivate Yes-associated protein (YAP) in primary lung fibroblasts undergoing fibrotic differentiation through modulation of HMG-CoA synthesizes, reduction of Geranylgeranyl Pyrophosphate (GGPP) synthesis and GGPP-mediated RhoA activation, which proposed a mechanism for the anti-fib…”
BackgroundXu, P., Zhang, J., Wang, M., Liu, B., Li, R., Li, H., Zhai, N., Liu, W., Lv, C., & Song, X. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.045 · Cited by 57
Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55
Metabolic perturbations in fibrosis disease
Ung, C. Y., Onoufriadis, A., Parsons, M., McGrath, J. A., & Shaw, T. J. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106073 · Cited by 61
Update in Interstitial Lung Disease 2020
Podolanczuk, A. J., Wong, A. W., Saito, S., Lasky, J. A., Ryerson, C. J., & Eickelberg, O. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202103-0559up · Cited by 68
The Role of Hippo/YAP Signaling in Alveolar Repair and Pulmonary Fibrosis
Gokey, J. J., Patel, S. D., & Kropski, J. A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.752316 · Cited by 49
Chen, Z., Xiao, L., Hu, C., Shen, Z., Zhou, E., Zhang, S., & Wang, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.015 · Cited by 47
YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis
Papavassiliou, K. A., Sofianidi, A. A., Spiliopoulos, F. G., Gogou, V. A., Gargalionis, A. N., & Papavassiliou, A. G. (2024) · Cells · doi:10.3390/cells13181519 · Cited by 46
“In another study, Santos et al. used high-throughput small-molecule screening on primary human lung fibroblasts and identified that hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, can target YAP [75].”
BackgroundInfluentialAnti-fibrotic effects of statin drugs: A review of evidence and mechanisms
Dolivo, D., Reed, C. R., Gargiulo, K. A., Rodrigues, A. E., Galiano, R. D., Mustoe, T. A., & Hong, S. J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115644 · Cited by 41
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Ezzo, M., & Hinz, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108528 · Cited by 41
Yıldırım, M., Kayalar, Ö., Atahan, E., & Öztay, F. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23074 · Cited by 36
Controlling cardiac fibrosis through fibroblast state space modulation
Reichardt, I. M., Robeson, K. Z., Regnier, M., & Davis, J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109888 · Cited by 36
“, 2020 [86] Simvastatinb Mouse Bleomycin-induced”
BackgroundA two-way street - cellular metabolism and myofibroblast contraction
Noom, A., Sawitzki, B., Knaus, P., & Duda, G. N. (2024) · npj Regenerative Medicine · doi:10.1038/s41536-024-00359-x · Cited by 31
“By inhibiting key points in the feedforward loop, such as the mevalonate pathway with statins 109 – 112 , glycolysis with Anlotinib 104 , lactate production by GSK2837808A 106 , or glutaminolysis with BPTES 107,108 , it might be possible to break the loop and thereby switch the fi brotic cascades…”
BackgroundHamrangsekachaee, M., Wen, K., Bencherif, S. A., & Ebong, E. E. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00449.2022 · Cited by 41
Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through α2β1 Integrin
Agarwal, M., Goheen, M., Jia, S., Ling, S., White, E. S., & Kim, K. K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0150oc · Cited by 34
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
Combining repurposed drugs to treat colorectal cancer
Duarte, D., & Vale, N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.012 · Cited by 32
Mechanobiology and the extracellular matrix in pulmonary fibrosis
Ganzleben, I., & Medoff, B. D. (2025) · iScience · doi:10.1016/j.isci.2025.113993 · Cited by 38
“386 Accordingly, HMG-CoA reductase inhibitors were capable of reducing fibrosis markers in both human fibroblasts and murine model systems of fibrosis by preventing an increased presence of YAP in the nucleus.”
Self-citationYAP-mediated trophoblast dysfunction: the common pathway underlying pregnancy complications
Lin, Q., Cao, J., Yu, J., Zhu, Y., Shen, Y., Wang, S., Wang, Y., Liu, Z., & Chang, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01371-2 · Cited by 23
“Among the FDA-approved drugs, statins have emerged as potent YAP inhibitors [154].”
BackgroundYoo, H., Singh, A., Li, H., Strat, A. N., Bagué, T., Ganapathy, P. S., & Herberg, S. (2023) · Current Eye Research · doi:10.1080/02713683.2023.2206067 · Cited by 19
“In another high-throughput library screen of more than 13,000 small-molecule compounds, simvastatin was found to exhibit strong YAP inhibitory effects via the same GGPP/Rho/actin signaling axis in human lung fibroblasts, and to reduce fibrotic markers in the bleomycin mouse model of pulmonary fibrosis.(82) Together, t…”
Novel mediators of idiopathic pulmonary fibrosis
Saito, S., Deskin, B., Rehan, M., Yadav, S., Matsunaga, Y., Lasky, J. A., & Thannickal, V. J. (2022) · Clinical Science · doi:10.1042/cs20210878 · Cited by 20
Ishikane, S., Arioka, M., & Takahashi‐Yanaga, F. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115663 · Cited by 19
Yang, Y., dos Santos, D. M., Pantano, L., Knipe, R. S., Abe, E. A., Logue, A., Pronzati, G., Black, K. E., Spinney, J. J., Giacona, F. L., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0428oc · Cited by 20
Self-citationStatins’ still controversial role in pulmonary fibrosis: What does the evidence show?
Andreikos, D., Karampitsakos, Τ., Tzouvelekis, A., & Stratakos, G. K. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102168 · Cited by 17
Bo, C., Liu, F., Zhang, Z., Du, Z., Xiu, H., Zhang, Z., Li, M., Zhang, W., & Jia, Q. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03014-9 · Cited by 17
“Moreover, Sim has anti-fibrotic properties by modulating the expression of Yes-associated proteins mediating the activation of mouse fibroblasts [44].”
Background[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
“For example, Santos et al. found that simva-statin inhibits YAP activity through the mevalonate pathway, disrupts pro fi brotic fi broblast di ff erentiation, alleviates pulmonary fi brosis in mice [104].”
RetractedThe Mechanical Role of YAP/TAZ in the Development of Diabetic Cardiomyopathy
Shen, J.-X., Zhang, L., Liu, H., Zhang, Z., Zhao, N., Zhou, J., Qian, L., & Wang, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050297 · Cited by 15
“Through a high-throughput small-molecule screen in primary human lung fibroblasts, multiple statins were discovered to inhibit YAP nuclear localization by inducing YAP phosphorylation, leading to cytoplasmic retention and subsequent degradation [127].”
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00295-1 · Cited by 15
“Statins and MK-5108 were screened for small molecules that inhibit the nuclear localization of YAP in primary human lung fibroblasts [84, 85] and are thought to indirectly prevent YAP from nuclear translocation; however, the mechanisms are not fully understood.”
BackgroundTension-induced organelle stress: an emerging target in fibrosis
Kai, F., Leidal, A. M., & Weaver, V. M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.006 · Cited by 11
Wang, Y., Geng, X., Sun, X., Cui, H., Guo, Z., Chu, D., Li, J., & Li, Z. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114352 · Cited by 10
Saito, Y., Xiao, Y. Q., Yao, J., Li, Y., Liu, W., Yuzhalin, A. E., Shyu, Y.-M., Li, H., Yuan, X., Li, P., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00720-w · Cited by 13
“Additionally, Statins, a class of lipid-lowering medications used to prevent cardiac disease, inhibit Yap1 nuclear localization and transcriptional responses in human cancer cells 24,25 .”
Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases
Kotlyarov, S. N. (2025) · Pathophysiology · doi:10.3390/pathophysiology32020026 · Cited by 11
An updated review of YAP: A promising therapeutic target against cardiac aging?
Leng, J., Wang, C., Liang, Z., Qiu, F., Zhang, S., & Yuan, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127670 · Cited by 12
Iannelli, F., Lombardi, R., Costantini, S., Roca, M. S., Addi, L., Bruzzese, F., Gennaro, E. D., Budillon, A., & Pucci, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03573-1 · Cited by 10
“However, some studies have suggested that the effect of statins is independent of MST1/2 and LATS1/2 activity [38, 39], whereas others have described a significant induction of LATS1 expression upon statin treatment [40, 41].”
Myasoedova, V. A., Rega, S., Valerio, V., Moschetta, D., Massaiu, I., Bonalumi, G., Esposito, G., Rusconi, V., Bertolini, F., Perrucci, G. L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1426982 · Cited by 7
Park, J., Lee, C., Han, K., & Choi, S. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-58417-9 · Cited by 10
“There is some experimental evidence supporting the anti-fibrotic potential of statins 24–26 , which are also known to have anti-inflammatory effects 27 .”
BackgroundDu, J., Qian, M., Yuan, T., Zhang, B., Chen, X., An, N., He, Q., Yang, B., Ye, S., & Zhu, H. (2022) · Acta Pharmaceutica · doi:10.2478/acph-2022-0029 · Cited by 6
“For example, statins act as mevalonate pathway inhibitors to interfere with the activation of Rho GTPases by inhibiting the HMGCR cascades, ultimately leading to YAP phosphorylation and cytoplasmic retention (23).”
BackgroundMohamed, R. H., Abdelrahim, D. S., hay, N. H. A., Fawzy, N. M., M., D. K. M., Yehia, D. A. Y., Abdel-Maksoud, O. M., & Tamim, Y. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-68303-z · Cited by 6
Ilg, M. M., Ralph, D. J., & Cellek, S. (2023) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdad051 · Cited by 5
Anfuso, B., Velnati, S., Selvestrel, D., Garlant, C., Ferracci, E., Baj, G., Parisse, P., Overi, D., Bertolio, R., Bulla, R., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116681 · Cited by 3
Yi, L., Chen, T., Zhou, Y., Zhu, P., Zhu, Q., Shao, Y., & Yao, W. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00477-6 · Cited by 5
“Beyond their lipid-lowering effects, statins have recently been shown to inhibit YAP nuclear localization by inducing its phosphorylation, cytoplasmic retention, and degradation, representing a potential non-canonical mechanism contributing to their anti-restenotic effects [187].”
Mechanosensing pathways in the progression of pulmonary fibrosis
Nieves, E. B., & García, A. J. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100598 · Cited by 4
Renin-Angiotensin-Aldosterone System Role in Organ Fibrosis
Ghanem, M., & Megahed, H. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-23621-1_12 · Cited by 4
Golubev, D., Zemskaya, N. V., Gorbunova, A. A., Kukuman, D. V., Moskalev, A., & Shaposhnikov, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066006 · Cited by 2
“Despite a large amount of experimental data having demonstrated a decrease in YAP/TAZ activity during physiological aging [19,23,24,29], a number of studies have shown that several compounds with proven anti-aging properties such as resveratrol [30], rapamycin [31], metformin [32], and simvastatin [33] inhibit transcr…”
BackgroundAdvances towards potential cancer therapeutics targeting Hippo signaling
Zhu, R., Jiao, Z., & Yu, F. (2024) · Biochemical Society Transactions · doi:10.1042/bst20240244 · Cited by 3
Roop, B. W., Calmo, N. M., Bass, A., Berigei, S. R., Knipe, R. S., Santos, D., DeCoursey, A., Lee, G., Turner, S., Herrmann, M. D., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03536-2 · Cited by 2
Self-citationYoo, H., Singh, A., Li, H., Strat, A. N., Bagué, T., Ganapathy, P. S., & Herberg, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.27.509788 · Cited by 2
Mia, M. M., Selvan, A., Nilanthi, U., & Singh, M. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.23.661212 · Cited by 5
Discovery of novel anti-fibrotics through phenotypic screening
Lapthorn, A. R., Harding, S. L., Feltham, K. M., Ilg, M. M., & Cellek, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104450 · Cited by 1
Gao, L., Chaher, N., Serralha, J. C., Bertolaccini, M. L., Velasco, C., da Cruz, G. J. L., Morrell, A. P., Prieto, C., Botnar, R. M., Smith, A., et al. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.125.018784 · Cited by 1
“29 30–32 Our histological analyses also showed that treatment with a statin reduced vein wall thickness following thrombosis.”
Liu, S., Ding, M., & Zhang, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124292 · Cited by 1
Papanikolaou, M. A., Gargalionis, A. N., Adamopoulos, C., & Piperi, C. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10349-8 · Cited by 1
“For example, statins indirectly activate LATS1/2 by reducing geranylgeranyl pyrophosphate (GGPP) levels, a LATS1/2 inhibitor [146].”
A Glowing Opportunity to Target YAP in Lung Fibrosis
Neubig, R. R. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0082ed · Cited by 2
“These authors recently showed (6) that statins could reduce YAP nuclear localization (using the same screening methodology), and statins may improve outcomes in IPF (7).”
BackgroundMechanotherapeutics for the Treatment of Idiopathic Pulmonary Fibrosis
Lagares, D., & Han, H. (2026) · Barcelona Respiratory Network · doi:10.23866/brnrev:2020-0012
Alsohime, F., Sharif‐Askari, N. S., Alharbi, N. S., Alosaimi, M. F. A., & Halwani, R. (2025) · International Archives of Allergy and Immunology · doi:10.1159/000548097 · Cited by 1
“As in the bleomycin model, the initial inflammatory phase was followed by a fibrotic phase, which was less evident in the blood [27–30].”
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24180899
Bo, C., Liu, F., Zhang, Z., Du, Z., Xiu, H., Zhang, Z., Li, M., Zhang, C., & Jia, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26718078
Bo, C., Liu, F., Zhang, Z., Du, Z., Xiu, H., Zhang, Z., Li, M., Zhang, C., & Jia, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26718069
Bo, C., Liu, F., Zhang, Z., Du, Z., Xiu, H., Zhang, Z., Li, M., Zhang, C., & Jia, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26718072
Bo, C., Liu, F., Zhang, Z., Du, Z., Xiu, H., Zhang, Z., Li, M., Zhang, C., & Jia, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26718075
The Hippo pathway in cardiac fibrosis: mechanisms and therapeutic prospects
Qiu, Y., Hu, S., Li, H., Ren, J., Liao, M., Huo, J., Luo, Z., & Lu, L. (2026) · Human Cell · doi:10.1007/s13577-026-01352-w · Cited by 1
“Simvastatin effectively reduces the activation of human lung fibroblasts and decreases fibrosis markers in the mouse model of pulmonary fibrosis [63].”
Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ Fibrosis
Pan, Z., Zerehpoosh, S., Wang, S.-C., Örmecİ, N., Kim, W., & Eslam, M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s566319 · Cited by 1
Targeting YAP: mechanistic breakthroughs and therapeutic prospects in reversing organ fibrosis
Fu, K., Cao, M., Wang, Y., Luo, J., & Yuan, W. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05540-y · Cited by 1
“In terms of metabolic regulation, statins inhibit YAP localization and activity via the mevalonate pathway, significantly reducing colla - gen deposition in bleomycin-induced pulmonary fibrosis mice [185].”
Metadata
- Authors
- Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., Bieler, M., Seither, P., Nicklin, P., Wyatt, D., Tager, A. M., & Medoff, B. D.
- Affiliations
- Division of Pulmonary and Critical Care Medicine, and
- Harvard University (US)
- Computational Chemistry
- Business Development and Licensing
- Research Beyond Borders, and
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Medoff, Benjamin D.
- ORCID
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-01
- Volume
- 62
- Issue
- 4
- Pages
- 479-492
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC7110981
- OpenAlex
- W3003235367
- Cited by
- 72
- References
- 76
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 7 · 2020: 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL133153, K08HL133603)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- YAP, YAP inhibitor, statins, simvastatin, idiopathic pulmonary fibrosis, lung fibroblasts, fibroblast activation, mevalonate pathway, YAP phosphorylation, antifibrotic agents, bleomycin-induced fibrosis
- MeSH terms
- YAP-Signaling Proteins, Acyl Coenzyme A, Animals, Bleomycin, Cell Nucleus, Cytoplasm, Fibroblasts, Humans, Mevalonic Acid, Phosphoproteins, Pulmonary Fibrosis, Signal Transduction, Biomarkers, Cell Cycle Proteins, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Adaptor Proteins, Signal Transducing, Mice, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.